BCMA-Targeting Antibody for Plasma Cell Depletion in Myeloma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma and autoimmune diseases, such as multiple myeloma and systemic lupus erythematosus, are limited by side effects, high costs, and incomplete efficacy, particularly due to the challenge of specifically targeting plasma cells and long-lived plasma cells that resist conventional therapies.
Innovation Solution
Development of antibodies or antibody fragments that bind specifically to the extracellular domain of CD269 (BCMA), disrupting the interaction with its native ligands BAFF and APRIL, thereby inhibiting the survival and growth signals for malignant plasma cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat multiple myeloma and autoimmune diseases, then treatment can be administered, but side effects increase and efficacy is incomplete due to inability to specifically target plasma cells
Solution Approach 1:
The invention uses antibodies that specifically target BCMA expressed on plasma cells, segmenting the treatment effect to act only on the specific cell type responsible for the disease, leaving other healthy cells unaffected. This resolves the contradiction by achieving reliable therapeutic efficacy through specific targeting while avoiding side effects from non-specific damage to other cells.
Solution Approach 2:
The antibody serves as an intermediary that bridges the treatment agent and the specific target (BCMA on plasma cells). This intermediary enables selective delivery of therapeutic effect to pathogenic plasma cells while sparing other cells, thereby improving efficacy without increasing harmful side effects.
2Reliability
If conventional therapies are used, then treatment can be provided, but costs are high and complete remission is rarely achieved
Solution Approach 1:
By segmenting the therapeutic approach to specifically target BCMA on plasma cells rather than using broad-spectrum conventional therapies, the invention achieves complete remission in cases where conventional treatments fail, improving the reliability of complete remission while potentially reducing long-term costs by avoiding chronic multi-drug regimens.
Solution Approach 2:
The invention changes the target parameter from general immune suppression or cytotoxicity to specific BCMA-mediated plasma cell depletion. This parameter change enables complete remission by directly eliminating the pathogenic cell population, improving therapeutic reliability while the single-target approach may reduce overall treatment costs compared to combination therapies.
3Reliability
If long-lived plasma cells are targeted, then therapeutic efficacy can be improved, but these cells resist conventional therapies making targeting difficult
Solution Approach 1:
The antibody treatment segments the targeting approach to specifically recognize BCMA on long-lived plasma cells, enabling depletion of these resistant cells through a simple single-agent mechanism rather than complex combination therapies, thereby improving reliability of plasma cell depletion without increasing device or treatment complexity.
Solution Approach 2:
The anti-BCMA antibody acts as a specific intermediary that overcomes the resistance of long-lived plasma cells to conventional therapies by targeting their unique BCMA marker, achieving reliable depletion of these previously untouchable cells through a straightforward specific binding mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively block the interaction between BCMA and its ligands, leading to the depletion of pathogenic plasma cells and improved therapeutic outcomes with reduced side effects and enhanced efficacy compared to existing treatments.
Implementation Method 1
antibodies or antibody fragments that bind specifically to the extracellular domain of CD269 (BCMA), disrupting the interaction with its native ligands BAFF and APRIL
Data Source
AI summary
A composition comprising a cell or a population thereof, wherein the cell comprises a polynucleotide encoding an antibody or a fragment thereof that binds CD269 (BCMA), wherein the binding to CD269 (BCMA) disrupts the interaction between CD269 and its native ligands (BAFF and APRIL). Also disclosed is treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.